Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations

Israel Medical Association Journal

Volumn 15, Issue 10, 2013, Pages 617-621

  Sakem, Benjamin ^a   Matozan, Katja ^a   Nydegger, Urs E ^a   Weigel, Guenter ^b   Griesmacher, Andrea ^b   Risch, Lorenz ^a,b  

^a Center for Laboratory Medicine Dr Risch   (Switzerland)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Free light chains (FLC); Hemagglutination; Intravenous immunoglobulin (IVIG); Phospholipids; Red blood cells

Indexed keywords

EPITOPE; ERYTHROCYTE ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ANTIBODY SCREENING; ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMAGGLUTINATION; HUMAN; MALE; NEPHELOMETRY; SCREENING TEST;

ABO BLOOD-GROUP SYSTEM; ANTIBODIES, ANTIPHOSPHOLIPID; ERYTHROCYTES; HEMAGGLUTINATION TESTS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; ISOANTIBODIES; NEPHELOMETRY AND TURBIDIMETRY;

EID: 84887161256     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kahwaji J, Barker E, Pepkowith S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009; 4 (12): 1993-7.
2. Morgan S, Sorensen P, Vercellotti G, Zantek ND. Hemolysis after treatment with intravenous immunoglobulin due to anti-A. Transfus Med 2011; 21 (4): 267-70.
3. Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008; 48 (8): 1598-601.
4. Buchs JP, Nydegger UE. Development of an ABO-ELISA for the quantitation of human blood group anti-A and anti-B IgM and IgG antibodies. J Immunol Methods 1989; 118 (1): 37-46.
5. Torpe SJ, Fox B, Sharp G, et al. International collaborative study to establish reference preparations to standardise haemagglutination testing for anti-A and anti-B in normal intravenous immunoglobulins by the direct method. Pharmeur Bio Sci Notes 2010 (1): 39-50.
6. Lin HH, Wanng M, Spies JM, Pollard JD. Effective treatment of experimental autoimmune neuritis with Fc fragment of human immunoglobulin. J Neuroimmunol 2007; 186 (1): 133-40.
7. Anthony RM, Ravetch JV. A novel role for the IgG glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010; 30 (Suppl 1): S9-14.
8. Mitsumori A, Shimada M, Jie X, Higuchi H, Groot Kormeling T, Redegeld FA. Effects of free immunoglobulin light chains on viral myocarditis. Circ Res 2010; 106 (9): 1533-40.
9. Masai R, Wakui H, Togashi M, et al. Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. Clin Nephrol 2009; 71: 9-20.
10. Rajabally YA, Kearney DA. Tromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study. J Neurol Sci 2011; 308 (1-2): 124-7.
11. Mizrahi M. Te hypercoagulability of intravenous immunoglobulin. Clin Adv Hematol Oncol 2011; 9 (1): 49-50.
12. Salama A, Schwind P, Schonhage K, et al. Rapid detection of antibodies to immunoglobulin A molecules by using the particle gel immunoassay. Vox Sang 2001; 81 (1): 45-8.
13. Shoham-Kessary H, Gershon H. Isoantibodies in immunoglobulin for intravenous use may cause erythrocyte sequestration. Vox Sang 1999; 77: 33-9.
14. Torpe SJ, Fox BJ, Dolman CD, Torpe R. Anti-A and anti-B activity in batches of different intravenous immunogloblin products determined using a direct haemagglutination method. Biologicals 2005; 33 (2): 111-16.
15. Spalter SH, Kaveri SV, Bonnin E, Mani JC, Cartron JP, Kazatchkine MD. Normal human serum contains natural antibodies reactive with autologous ABO blood group antigens. Blood 1999; 93 (12): 4418-24.
16. Stussi G, Huggel K, Lutz HU, Schanz U, Rieben R, Seebach JD. Isotype-specific detection of ABO blood group antibodies using a novel flow cytometric method. Br J Haematol 2005; 130: 954-63.
17. Renner FC, Wienzk-Lischka S, Feustel A, et al. Impact of pretransplant intravenous immunoglobulin administration on anti-ABO antibody levels in ABO-incompatible living donor kidney transplantation. Transplant Proc 2010; 42 (10): 4003-5.
18. Mueller RJ, Stussi G, Yung GP, et al. Persistence of recipient type endothelium after allogeneic hematopoietic stem cell transplantation. Haematologica 2011; 96 (1): 119-27.
19. Myatt EA, Westholm FA, Weiss DT, Solomon A, Schiffer M, Stevens FJ. Pathogenic potential of human monoclonal immunoglobulin light chains: relatioonship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci USA 1994; 91: 3034-8.
20. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney - a two-edged sword. Semin Arthritis Rheum 2004; 34: 593-601.
21. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375: 1721-8.
22. Foster R, Suri A, Filate W, et al. Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes. Transfus Med 2010; 20 (6): 403-8.
23. Baxley A, Akhtari M. Hematologic toxicities associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2011; 11 (11): 1663-7.
24. Berard R, Whittemore B, Scuccimarri R. Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases. Pediatr Rheumatol 2012; 10: 10.
25. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-96.